Form 4: CEO Brian Webster Sells Kestra Medical Shares
Statement of Changes in Beneficial Ownership
Kestra Medical Technologies CEO Brian Daniel Webster sold 15,000 common shares via a pre-arranged Rule 10b5-1 trading plan.
Summary
- Reporting person Brian Daniel Webster, President and CEO of Kestra Medical Technologies, sold a total of 15,000 common shares on May 15, 2026.
- The sales were executed in two tranches: 8,155 shares at a weighted average price of $20.5287 and 6,845 shares at a weighted average price of $21.4635.
- Following these transactions, the reporting person retains beneficial ownership of 334,786 common shares.
- The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted through a pre-planned, automated trading program rather than a discretionary market move.
Positives
- The sale was executed under a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for executives to sell shares without triggering insider trading concerns.
Negatives
- The sale represents a reduction in the CEO's direct equity stake in the company.
Risks
- Market perception of insider selling can sometimes lead to short-term downward pressure on the stock price.
Future Outlook
No specific forward-looking guidance regarding company operations was provided in this filing.
Industry Context
StockSavvy.ai notes that routine insider selling via 10b5-1 plans is a common practice for executives to diversify personal wealth and is generally viewed as non-indicative of company performance or management sentiment.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is the industry standard for corporate executives to manage equity holdings while maintaining compliance with SEC regulations.
Stakeholder Impact
- Shareholders should note the reduction in CEO equity, though the use of a 10b5-1 plan mitigates concerns regarding potential non-public information usage.
Next Steps
- Continued monitoring of future Form 4 filings for further changes in insider holdings.
Key Dates
| Date | Description |
|---|---|
| 09/29/2025 | Adoption date of the Rule 10b5-1 trading plan. |
| 05/15/2026 | Date of the reported share sale transactions. |
| 05/18/2026 | Date of the filing signature. |
Keywords
Kestra Medical Technologies, KMTS, Insider Trading, Form 4, Brian Daniel Webster, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.